Tag Archives: Anthony Vendetti

Maxim Group Sticks to Its Buy Rating for Landec Corp (LNDC)

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Landec Corp (LNDC – Research Report), with a price target of $17. The company’s shares closed yesterday at $9.66, close to its 52-week low of

Maxim Group Keeps a Hold Rating on Applied DNA Sciences (APDN)

Maxim Group analyst Anthony Vendetti maintained a Hold rating on Applied DNA Sciences (APDN – Research Report) yesterday. The company’s shares opened today at $0.59. Vendetti commented: “2019, APDN announced that its cannabis partner, TheraCann International (private), secured an agreement

Maxim Group Remains a Buy on Yield10 Bioscience Inc (YTEN)

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Yield10 Bioscience Inc (YTEN – Research Report) yesterday and set a price target of $3. The company’s shares closed yesterday at $0.80, close to its 52-week low of $0.68. Vendetti

Analysts Offer Insights on Healthcare Companies: PAVmed Inc (NASDAQ: PAVM) and Aurinia Pharmaceuticals (NASDAQ: AUPH)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PAVmed Inc (PAVM – Research Report) and Aurinia Pharmaceuticals (AUPH – Research Report) with bullish sentiments. PAVmed Inc (PAVM) In a report

Maxim Group Sticks to Its Hold Rating for Restoration Robotics Inc (HAIR)

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Hold rating on Restoration Robotics Inc (HAIR – Research Report). The company’s shares opened today at $0.53, close to its 52-week low of $0.35. Vendetti said: “Market close,

Analysts Offer Insights on Healthcare Companies: Ra Medical Systems Inc (NYSE: RMED), Atara Biotherapeutics (NASDAQ: ATRA) and Allena Pharmaceuticals Inc (NASDAQ: ALNA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ra Medical Systems Inc (RMED – Research Report), Atara Biotherapeutics (ATRA – Research Report) and Allena Pharmaceuticals Inc (ALNA – Research Report)